Tina Hartert

Assessment of New Recommendations for RSV Vaccination in 50-59 Year Old High Risk Adults on Short- and Long-Term Cardiorespiratory Outcomes

National Institute of Allergy and Infectious Diseases · R01

PI · $818.1K · Vanderbilt University Medical Center

Viral and Host Determinants of Infant and Childhood Allergy and Asthma

National Institute of Allergy and Infectious Diseases · U19

Contact PI · $22.7M · Vanderbilt University Medical Center

ECHO Renewal for the INSPIRE Study Cohort

NIH Office of the Director · UH3

Contact PI · $2.7M · Vanderbilt University Medical Center

Establishing Critical Time Windows of Infant RSV Infection in the Causal Relationship of RSV and Childhood Asthma

National Heart, Lung, and Blood Institute · R01

PI · $2.3M · Vanderbilt University Medical Center

Randomized Controlled Trial of Silymarin in Asthma

Principal investigator · Withdrawn · Phase 2, Phase 3

Vanderbilt University

COVID-19: Human Epidemiology and Response to SARS-CoV-2

Study chair · Completed

National Institute of Allergy and Infectious Diseases (NIAID)